Weeks af­ter launch­ing Aeter­na Zen­taris castoff, Strong­bridge turns around and sells rights to No­vo Nordisk — at a pre­mi­um

Reach­ing what ap­pears to be an end to its wind­ing jour­ney to mar­ket, the growth hor­mone drug Macrilen has just found a new home in the US and Cana­da.

No­vo Nordisk has scooped up re­gion­al rights to the as­set from Strong­bridge Bio­phar­ma, which bought them from Aeter­na Zen­taris this Jan­u­ary for $24 mil­lion up­front and some mile­stones. That’s a bar­gain price com­pared to what the Dan­ish drug­mak­er is of­fer­ing now: $145 mil­lion, plus an eq­ui­ty in­vest­ment worth more than $36 mil­lion as well as tiered roy­al­ties through 2027.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER